|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2017
|
|
gptkbp:ATCCode
|
gptkb:R03DX10
|
|
gptkbp:brand
|
gptkb:Fasenra
|
|
gptkbp:CASNumber
|
gptkb:1044511-01-3
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
immunosuppressant
|
|
gptkbp:eliminationHalfLife
|
15-20 days
|
|
gptkbp:hasMolecularFormula
|
C6502H10004N1732O2036S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Benralizumab
|
|
gptkbp:indication
|
severe asthma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonist of IL-5 receptor alpha
|
|
gptkbp:monoclonalAntibodyType
|
gptkb:IgG1_kappa
|
|
gptkbp:pregnancyCategory
|
unknown
|
|
gptkbp:prescribes
|
adolescents
adults
|
|
gptkbp:reduces
|
eosinophil levels
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
fever
headache
injection site reaction
rash
pharyngitis
|
|
gptkbp:target
|
gptkb:interleukin-5_receptor_alpha
|
|
gptkbp:UNII
|
3ZJ8QY2W0V
|
|
gptkbp:usedFor
|
gptkb:eosinophilic_asthma
asthma
|
|
gptkbp:bfsParent
|
gptkb:NCT02667587
|
|
gptkbp:bfsLayer
|
6
|